RFA-CA-23-017 (U24 Sustainment): Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

Globus allows cancer researchers to securely move, sync, and share their data no matter the data scale or location, whether on their laptop, in the cloud, at campus provided storage, or at high performance computing centers. Globus services can be integrated into applications and research data gateways, providing developers with reliable data management, identity management, search, and automation capabilities.
CNVpytor is a tool for germline and mosaic copy number variation detection and analysis from read depth and allele imbalance in whole-genome sequencing.
FeTS and OpenFL are open-source tools facilitating de-centralized multi-site collaborations via federated machine learning (FL), without sharing patient/sensitive data and while addressing health disparities and inequities. FeTS focuses on harmonized image curation, generation of reference labels, and de-centralized training of tumor segmentation models leveraging OpenFL, which is agnostic to the use case & offers a general-purpose FL mechanism.
This special issue of JCO Clinical Cancer Informatics,
“Informatics Tools for Cancer Research and Care – Bridging
the Gap Between Innovation and Implementation,” features
30 open access articles describing select ITCR tools.
ITCR has issued four Funding Opportunity Announcements aimed at successive stages of informatics technology development.
RFA-CA-23-017 (U24 Sustainment): Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
RFA-CA-23-016 (U24 Advanced Development): Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
RFA-CA-23-015 (U01): Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
RFA-CA-23-014 (R21): Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)